Imatinib, sold under the brand names Gleevec and Glivec, used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Due in large part to the development of Gleevec and related drugs having a similar mechanism of action, the five year survival rate for people with chronic myeloid leukemia nearly doubled from 31% in 1993 (before Gleevec's 2001 FDA approval) to 59% for those diagnosed between 2003 and 2009.
- ProName: Imatinib
- CasNo:152459-95-5
- Molecular Formula: C30H35N7O4S
- Appearance: White powder
- Application: drug used to treat certain types of ca...
- DeliveryTime: prompt shipment
- PackAge: 100g/bag, 500g/bag,or at customer's re...
- Port: Shanghai,China
- ProductionCapacity: 20 Kilogram/Day
- Purity: 99%min
- Storage: RT
- Transportation: by air,sea
- LimitNum: 1 Kilogram
No comments:
Post a Comment